The primary endpoint (a composite of LVAD thrombosis and ischemic stroke) was significantly lower in the PDE-5i group compared with the no-PDE-5i group (hazard ratio (HR), 0.84; 95% CI, 0.77–0.91; p < 0.001) at 48 months. The gene discussed is ALDH7A1; the disease is ischemic stroke.